首页> 美国卫生研究院文献>Acta Bio Medica : Atenei Parmensis >Lactobacillus plantarum LP01 Lactobacillus lactis subspecies cremoris LLC02 and Lactobacillus delbrueckii LDD01 in patients undergoing bowel preparation
【2h】

Lactobacillus plantarum LP01 Lactobacillus lactis subspecies cremoris LLC02 and Lactobacillus delbrueckii LDD01 in patients undergoing bowel preparation

机译:接受肠准备的患者中的植物乳杆菌LP01乳酸乳亚种cremoris LLC02和德氏乳杆菌LDD01

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Bowel preparation (BP) for colonoscopy induces significantly changes in gut microbiota and elicit intestinal symptoms. Impaired microbiota causes an intestinal dysbiosis. Consequently, probiotics may counterbalance the disturbed microbiota after BP. The current survey evaluated the efficacy and safety of Abincol®,an oral nutraceuticalcontaining a probiotic mixture with LP01 (1 billion of living cells), LLC02 (800 millions of living cells), and LDD01 (200 millions of living cells), in 2,979 outpatients (1,579 males and 1,400 females, mean age 56 years) undergoing BP. Patients took 1 stick/daily for 4 weeks after colonoscopy. Abincol® significantly diminished the presence and the severity of intestinal symptoms and improved stool form. In conclusion, the current survey suggests that Abincol® may be considered an effective and safe therapeutic option in the management of patients undergoing BP. ( )
机译:用于结肠镜检查的肠道准备液(BP)会引起肠道菌群的显着变化并引起肠道症状。微生物群受损会引起肠道营养不良。因此,益生菌可以抵消BP后受干扰的微生物群。本次调查评估了含2种益生菌与LP01(10亿个活细胞),LLC02(8亿个活细胞)和LDD01(2亿个活细胞)的益生菌混合物的口服营养保健品Abincol®在2,979名门诊患者中的功效和安全性。 (1579例男性和1400例女性,平均年龄56岁)接受了BP。结肠镜检查后,患者每天服用1支/棒,持续4周。 Abincol®显着减少了肠道症状的出现和严重程度,并改善了粪便形式。总而言之,当前调查表明,在治疗BP的患者中,Abincol®可被视为一种有效且安全的治疗选择。 ()

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号